merck & co. inc. - MRK

MRK

Close Chg Chg %
119.72 2.17 1.81%

Closed Market

121.89

+2.17 (1.81%)

Volume: 13.08M

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Company Overview: merck & co. inc. - MRK

MRK Key Data

Open

$121.15

Day Range

120.44 - 122.66

52 Week Range

73.31 - 122.66

Market Cap

$293.70B

Shares Outstanding

2.48B

Public Float

2.48B

Beta

0.29

Rev. Per Employee

N/A

P/E Ratio

16.45

EPS

$6.10

Yield

273.90%

Dividend

$0.85

EX-DIVIDEND DATE

Mar 16, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

14.32M

 

MRK Performance

1 Week
 
10.57%
 
1 Month
 
10.31%
 
3 Months
 
41.32%
 
1 Year
 
39.70%
 
5 Years
 
60.86%
 

MRK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About merck & co. inc. - MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK At a Glance

Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065
Phone 1-908-740-4000 Revenue 65.01B
Industry Pharmaceuticals: Major Net Income 18.25B
Sector Health Technology 2025 Sales Growth 1.623%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

MRK Valuation

P/E Current 16.446
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.456
Price to Sales Ratio 4.059
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

MRK Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

MRK Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

MRK Profitability

Gross Margin 81.50
Operating Margin 41.191
Pretax Margin 32.405
Net Margin 28.078
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

MRK Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Merck & Co. Inc. - MRK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
58.47B 59.87B 63.97B 65.01B
Sales Growth
+19.56% +2.39% +6.85% +1.62%
Cost of Goods Sold (COGS) incl D&A
17.21B 15.98B 16.80B 12.03B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 3.91B 3.87B 4.50B
Depreciation
- 1.82B 1.83B 2.10B
Amortization of Intangibles
- 2.08B 2.04B 2.40B
COGS Growth
+27.77% -7.14% +5.16% -28.42%
Gross Income
41.27B 43.89B 47.17B 52.98B
Gross Income Growth
+16.44% +6.37% +7.47% +12.32%
Gross Profit Margin
+70.57% +73.31% +73.74% +81.50%
2022 2023 2024 2025 5-year trend
SG&A Expense
21.77B 40.91B 26.53B 26.20B
Research & Development
11.82B 30.53B 15.79B 15.60B
Other SG&A
9.95B 10.38B 10.73B 10.61B
SGA Growth
+9.81% +87.96% -35.16% -1.21%
Other Operating Expense
- - - -
-
Unusual Expense
2.27B 1.03B 1.18B 5.56B
EBIT after Unusual Expense
17.23B 1.95B 19.46B 21.22B
Non Operating Income/Expense
174.00M 1.08B 1.74B (151.00M)
Non-Operating Interest Income
- 157.00M 365.00M 415.00M
Equity in Earnings of Affiliates
- (1.42B) (106.00M) (29.00M)
Interest Expense
- 962.00M 1.15B 1.27B
Interest Expense Growth
- +19.35% +19.13% +10.91%
Gross Interest Expense
- 962.00M 1.15B 1.27B
Interest Capitalized
- - - -
-
Pretax Income
16.44B 1.89B 19.94B 21.07B
Pretax Income Growth
+18.48% -88.51% +955.37% +5.67%
Pretax Margin
+28.12% +3.16% +31.16% +32.41%
Income Tax
1.92B 1.51B 2.80B 2.80B
Income Tax - Current - Domestic
- 2.32B 976.00M 929.00M
Income Tax - Current - Foreign
- 1.16B 2.44B 3.12B
Income Tax - Deferred - Domestic
- (1.64B) (1.67B) (1.46B)
Income Tax - Deferred - Foreign
- 71.00M (233.00M) 212.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (1.42B) (106.00M) (29.00M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.53B 377.00M 17.13B 18.26B
Minority Interest Expense
7.00M 12.00M 16.00M 9.00M
Net Income
14.52B 365.00M 17.12B 18.25B
Net Income Growth
+17.61% -97.49% +4,589.59% +6.64%
Net Margin Growth
+24.83% +0.61% +26.76% +28.08%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
14.52B 365.00M 17.12B 18.25B
Preferred Dividends
- - - -
-
Net Income Available to Common
14.52B 365.00M 17.12B 18.25B
EPS (Basic)
- 5.7342 0.1439 6.7603
EPS (Basic) Growth
- +11.18% -97.49% +4,597.92%
Basic Shares Outstanding
- 2.53B 2.54B 2.53B
EPS (Diluted)
5.7116 0.1433 6.7363 7.2812
EPS (Diluted) Growth
+11.09% -97.49% +4,600.84% +8.09%
Diluted Shares Outstanding
2.54B 2.55B 2.54B 2.51B
EBITDA
- 23.41B 6.85B 25.14B
EBITDA Growth
- +24.30% -70.72% +266.84%
EBITDA Margin
- +40.04% +11.45% +39.30%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 120.13
Number of Ratings 29 Current Quarters Estimate -1.504
FY Report Date 03 / 2026 Current Year's Estimate 5.238
Last Quarter’s Earnings 2.04 Median PE on CY Estimate N/A
Year Ago Earnings 8.98 Next Fiscal Year Estimate 9.794
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 15 20 21
Mean Estimate -1.50 2.13 5.24 9.79
High Estimates -1.36 2.27 6.21 10.87
Low Estimate -1.72 1.90 5.00 9.10
Coefficient of Variance -6.49 4.93 5.48 4.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 13
OVERWEIGHT 2 2 2
HOLD 13 13 13
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Merck & Co. Inc. - MRK

Date Name Shares Transaction Value
Jan 29, 2026 Joseph Romanelli President, Human Health Int?l 28,739 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,086,568.60
Jan 29, 2026 David Michael Williams EVP,Chief Info&Digital Officer 30,838 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,312,001.20
Jan 29, 2026 Dalton E. Smart SVP Fin. - Global Controller 10,605 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 1,138,977.00
Jan 29, 2026 Jennifer Zachary EVP, General Counsel 68,916 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 7,401,578.40
Jan 29, 2026 Chirfi Guindo Chief Marketing Officer 100,615 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 10,806,051.00
Jan 29, 2026 Sanat Chattopadhyay Exe V-P & Pres. MMD 13,880 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 1,490,712.00
Jan 29, 2026 Johannes Jacobus Oosthuizen President, U.S. Market 36,197 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 3,887,557.80
Jan 29, 2026 Caroline A. Litchfield EVP & CFO 90,192 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 9,686,620.80
Jan 29, 2026 Richard R. DeLuca EVP&Pres, Merck Animal Heallth 197,859 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 21,250,056.60
Jan 29, 2026 Dean Y. Li Executive VP & President, MRL 102,270 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 10,983,798.00
Jan 29, 2026 Robert M. Davis Chairman, CEO & President; Director 491,036 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $107.4 per share 52,737,266.40
Jan 6, 2026 Mary Ellen Coe Director 29,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Thomas Henry Glocer Director 103,425 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Paul B. Rothman Director 31,991 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Stephen L. Mayo Director 12,540 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Kathy J. Warden Director 15,504 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Douglas M. Baker Director 9,344 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Risa J. Lavizzo-Mourey Director 15,367 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Patricia Fiorello Russo Director 58,523 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Inge G. Thulin Director 24,764 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Merck & Co. Inc. in the News